Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07300293

Lactic Acidosis and Prior Metformin Treatment

Prognosis of Lactic Acidosis Upon Admission to Intensive Care According to the Existence of Prior Treatment With Metformin

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Metformin is a drug frequently prescribed to patients with type 2 diabetes. Furthermore, diabetes can lead to micro- and macrovascular complications that may cause chronic organ failure. The presence of diabetes also increases the risk of infections. All of these factors contribute to the frequent admission of patients to the ICU who have been receiving metformin treatment in the preceding days. Acute renal failure, which is also frequently observed upon admission to the ICU, increases the risk of metformin overdose. In cases of overdose, metformin acts on several metabolic pathways that can lead to or even accelerate metabolic acidosis, sometimes severe. However, the impact on prognosis is controversial. The role of metformin in lactic acidosis in patients treated for acute illness may be underestimated in routine practice. This study aims to investigate the impact of prior metformin treatment on ICU survival in patients admitted to the ICU with severe lactic acidosis.

Conditions

Timeline

Start date
2024-11-06
Primary completion
2026-05-01
Completion
2026-05-01
First posted
2025-12-23
Last updated
2025-12-23

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07300293. Inclusion in this directory is not an endorsement.